コンテンツへスキップ
MediciNova, Inc.
　　Message from CEO
　　Our Mission
　　Company Profile
　　Management Team
　　History
　　Ongoing Clinical Studies
　　　　About MN-166 (Ibudilast)
　　　　ALS
　　　　Oncology / Glioblastoma
　　　　DCM
　　　　CIPN
　　　　ARDS / Lung Injury
　　　　About MN-001（Tipelukast)
　　　　NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
　　Press Release
　　Event
　　Media Archive
　　Annual Report
　　SEC filing
　　Stock Quote -TSE
　　Stock Quote -Nasdaq
　　Historical Price Lookup
　　Investment Calculator
　　Analyst Coverage
　　Corporate Governance
　　Information Request
　　Corporate Presentation & Resarch Reports
　　　　Progressive Multiple Sclerosis (Progressive MS)
　　　　Amyotrophic Lateral Sclerosis (ALS)
　　　　Oncology / Glioblastoma
　　　　Substance Dependence and Addiction
　　　　MN-166 (ibudilast) News Articles
　　　　MN-166 (ibudilast) Publications
　　MN-001 Presentation
　　Contact Us
Japanese site
  • About Us
    • Message from CEO
    • Our Mission
    • Company Profile
    • Management Team
    • History
  • Clinical Development
    • Ongoing Clinical Trial
    • MN-166 (Ibudilast)
      • About MN-166 (Ibudilast)
      • ALS
      • Oncology / Glioblastoma
      • DCM
      • CIPN
      • ARDS / Lung Injury
    • MN-001 ( tipelukast)
      • About MN-001（Tipelukast)
      • NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
  • Presentation
    • MN-166 Presentation
      • Progressive Multiple Sclerosis (Progressive MS)
      • Amyotrophic Lateral Sclerosis (ALS)
      • Oncology / Glioblastoma
      • Substance Dependence and Addiction
      • MN-166 (ibudilast) News Articles
      • MN-166 (ibudilast) Publications
    • MN-001 Presentation
  • Investor Relations
    • News
    • Events
    • Presentations
    • Stock Quote & Chart
    • TSE Stock Quote
    • Analyst Coverage
    • Equity Research
    • SEC Filings
    • Annual Reports
    • Documents & Charters
    • Email Alerts
  • Contact Us

MediciNova CEO Provides Shareholder Update

2026.06.302026.08.16
Page Top
Keenan Flogerzi
MediciNova, Inc.

関連記事

MN-166

MN-166のALS（筋萎縮性側索硬化症）を適応とする臨床治験においてNIV（非侵襲的換気補助器）のサポートを受ける進行ALS患者を対象とする修正プロトコルにおける患者登録開始のお知らせ

MN-166

MediciNova Announces Kick-off Meeting to Officially Launch Phase 3 Trial of MN 166 (ibudilast) in ALS

MN-001

MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society

MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025

MN-001

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea

MN-166

MN-166のアルコール依存症を適応とするフェーズ2a臨床治験の患者登録完了のお知らせ

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN-166 (ibudilast) in ALS patients
Copyright © 2021 MEDICINOVA, Inc. All Rights Reserved. | Terms of Use | Privacy Policy
    • About Us
      • Message from CEO
      • Our Mission
      • Company Profile
      • Management Team
      • History
    • Clinical Development
      • Ongoing Clinical Trial
      • MN-166 (Ibudilast)
        • About MN-166 (Ibudilast)
        • ALS
        • Oncology / Glioblastoma
        • DCM
        • CIPN
        • ARDS / Lung Injury
      • MN-001 ( tipelukast)
        • About MN-001（Tipelukast)
        • NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
    • Presentation
      • MN-166 Presentation
        • Progressive Multiple Sclerosis (Progressive MS)
        • Amyotrophic Lateral Sclerosis (ALS)
        • Oncology / Glioblastoma
        • Substance Dependence and Addiction
        • MN-166 (ibudilast) News Articles
        • MN-166 (ibudilast) Publications
      • MN-001 Presentation
    • Investor Relations
      • News
      • Events
      • Presentations
      • Stock Quote & Chart
      • TSE Stock Quote
      • Analyst Coverage
      • Equity Research
      • SEC Filings
      • Annual Reports
      • Documents & Charters
      • Email Alerts
    • Contact Us
  • MediciNova, Inc.